Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Santen Pharmaceutical Co's change in inventory for the quarter that ended in Mar. 2026 was $-29 Mil. It means Santen Pharmaceutical Co's inventory
increased by $29 Mil
from Dec. 2025 to Mar. 2026 .
Santen Pharmaceutical Co's change in inventory for the fiscal year that ended in Mar. 2026 was $-63 Mil. It means Santen Pharmaceutical Co's inventory
increased by $63 Mil
from Mar. 2025 to Mar. 2026 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Santen Pharmaceutical Co's Days Inventory for the quarter that ended in Mar. 2026 was 197.34.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Santen Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.46.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Santen Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.78.
Santen Pharmaceutical Co (OTCPK:SNPHF) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Santen Pharmaceutical Co's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Santen Pharmaceutical Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co Change In Inventory Related Terms
Santen Pharmaceutical Co Change In Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co Change In Inventory Chart
Santen Pharmaceutical Co Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHF) has a Change In Inventory of $-67 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Change In Inventory too high?
Santen Pharmaceutical Co's current Change In Inventory is $-67 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Change In Inventory compare to LLY and JNJ?
Santen Pharmaceutical Co's Change In Inventory of $-67 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Change In Inventory is $-67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.23, compared to a current price of $13.05 — trading 27.6% above its estimated fair value. The current Change In Inventory is $-67 Mil. Santen Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Change In Inventory is $-67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 27.6% above its estimated GF Value™ of $10.23.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHF:
Change In Inventory: $-67 Mil
GF Value™: $10.23 vs. price of $13.05 (27.6% above fair value)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
83GF Score
Get the complete analysis for SNPHF
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
